Achieve Life Sciences (ACHV) Tops Q4 EPS by 2c

Achieve Life Sciences (NASDAQ: ACHV) reported Q4 EPS of ($0.30), $0.02 better than the analyst estimate of ($0.32).

"With over 34 million smokers and nearly 11 million vape and e-cigarette users in the United States alone, the nicotine addiction epidemic continues to be a major public health crisis that Achieve is exclusively focused on addressing through the development of cytisinicline." commented Rick Stewart, Chairman and Chief Executive Officer of Achieve. "Our key priorities in the coming months are to initiate the ORCA-2 Phase 3 clinical trial in smokers and secure non-dilutive financing to evaluate cytisinicline specifically in the growing population of vape users."

For earnings history and earnings-related data on Achieve Life Sciences (ACHV) click here.

You May Also Be Interested In

• AAR prices $1.9 billion in senior notes to fund MRO Holdings deal
• Voyager Technologies, Inc. (VOYG) Misses Q3 EPS by 55c; Offer Guidance
• Parametric Sound (PAMT) Misses Q3 EPS by 31c